Sign In
Buy VERA
$31.58
-1.31 (-3.98%)
At Close: Aug 10, 2026
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
08:00am, Friday, 02'nd Feb 2024
BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
BRISBANE, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patie
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
11:50pm, Monday, 29'th Jan 2024
BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patie
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
06:15am, Monday, 29'th Jan 2024
BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patie
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
06:30am, Thursday, 25'th Jan 2024
– Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment
Why Vera Therapeutics Stock Soared by 22% This Week
06:44pm, Friday, 12'th Jan 2024
The biotech added two new executives to its ranks. Both have considerable experience in healthcare industry management.
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D.
08:01am, Monday, 08'th Jan 2024
BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for pat
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 27'th Dec 2023
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street
10:15am, Friday, 15'th Dec 2023
Vera Therapeutics is a clinical stage company that some analysts think could be worth $1 billion. The company could have an approved product for the treatment of IgA nephropathy by 2026.
Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to Trade
11:17am, Tuesday, 14'th Nov 2023
The mean of analysts' price targets for Vera Therapeutics, Inc. (VERA) points to an 86.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
08:00am, Thursday, 09'th Nov 2023
BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Additional analysis of week 36 data from the Phase 2b ORIGIN study of atacicept demonstrating resolution of hematuria in the majority of IgAN patients.
Vera Therapeutics Scheduled to Present at November Investor Conferences
08:00am, Monday, 30'th Oct 2023
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatme
Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
11:19am, Wednesday, 18'th Oct 2023
The heavy selling pressure might have exhausted for Vera Therapeutics, Inc. (VERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St
Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
11:19am, Tuesday, 17'th Oct 2023
Vera Therapeutics, Inc. (VERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analys
